Senti Bio Announces New Strategic Collaboration With Celest Therapeutics For Clinical Development Of SENTI-301A In China; Senti Bio Eligible To Receive Up To $156M In Milestones And Royaltie
Portfolio Pulse from Benzinga Newsdesk
Senti Biosciences (NASDAQ:SNTI) has announced a strategic collaboration with China-based biotech company Celest Therapeutics for the clinical development of SENTI-301A, a therapy for solid tumors, in China. Celest will lead clinical development, operations, and manufacturing with technical support from Senti Bio. The first patient is expected to be enrolled in China in 1H 2024. Senti Bio could receive up to $156 million in milestone payments and potential tiered royalty payments. Senti Bio retains all commercialization rights outside of mainland China, Hong Kong, Macau, and Taiwan for SENTI-301A.
November 06, 2023 | 9:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Senti Biosciences has entered into a strategic collaboration with Celest Therapeutics for the clinical development of SENTI-301A in China. This could potentially bring in up to $156 million in milestone payments and royalties for Senti Bio.
The partnership with Celest Therapeutics opens up a new market for Senti Biosciences' SENTI-301A in China. The potential milestone payments and royalties of up to $156 million could provide a significant revenue boost for Senti Bio. This news is highly relevant and important for Senti Bio investors as it represents a significant business development and potential future revenue stream.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100